首页> 外文OA文献 >Heparin-binding protein (HBP) improves prediction of sepsis-related acute kidney injury
【2h】

Heparin-binding protein (HBP) improves prediction of sepsis-related acute kidney injury

机译:肝素结合蛋白(HBp)可改善脓毒症相关急性肾损伤的预测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Sepsis-related acute kidney injury (AKI) accounts for major morbidity and mortality among the critically ill. Heparin-binding protein (HBP) is a promising biomarker in predicting development and prognosis of severe sepsis and septic shock that has recently been proposed to be involved in the pathophysiology of AKI. The objective of this study was to investigate the added predictive value of measuring plasma HBP on admission to the intensive care unit (ICU) regarding the development of septic AKI. Methods: We included 601 patients with severe sepsis or septic shock from the prospective, observational FINNAKI study conducted in seventeen Finnish ICUs during a 5-month period (1 September 2011–1 February 2012). The main outcome measure was the development of KDIGO AKI stages 2–3 from 12 h after admission up to 5 days. Statistical analysis for the primary endpoint included construction of a clinical risk model, area under the receiver operating curve (ROC area), category-free net reclassification index (cfNRI) and integrated discrimination improvement (IDI) with 95% confidence intervals (95% CI). Results: Out of 511 eligible patients, 101 (20%) reached the primary endpoint. The addition of plasma HBP to a clinical risk model significantly increased ROC area (0.82 vs. 0.78, p = 0.03) and risk classification scores: cfNRI 62.0% (95% CI 40.5–82.4%) and IDI 0.053 (95% CI 0.029–0.075). Conclusions: Plasma HBP adds predictive value to known clinical risk factors in septic AKI. Further studies are warranted to compare the predictive performance of plasma HBP to other novel AKI biomarkers.
机译:背景:脓毒症相关的急性肾损伤(AKI)在重症患者中占主要的发病率和死亡率。肝素结合蛋白(HBP)是预测严重败血症和败血性休克的发展和预后的有前途的生物标志物,最近已提出该蛋白与AKI的病理生理有关。这项研究的目的是调查在接受重症监护病房(ICU)时关于血浆ABP的测定对血浆ABP的预测价值。方法:我们在5个月内(2011年9月1日至2012年2月1日)对17例芬兰重症监护病房进行了FINNAKI的前瞻性观察性研究,纳入了601名患有严重败血症或败血性休克的患者。主要结局指标是入院后12小时至5天KDIGO AKI 2-3期的进展。主要终点的统计分析包括临床风险模型的构建,接受者操作曲线下的面积(ROC面积),无类别净重分类指数(cfNRI)和综合辨别力改善(IDI),置信区间为95%(CI为95%) )。结果:在511名合格患者中,有101名(20%)达到了主要终点。在临床风险模型中增加血浆HBP可显着增加ROC面积(0.82 vs. 0.78,p = 0.03)和风险分类评分:cfNRI 62.0%(95%CI 40.5-82.4%)和IDI 0.053(95%CI 0.029-95) 0.075)。结论:血浆HBP为脓毒症AKI的已知临床危险因素增加了预测价值。有必要进行进一步的研究,以比较血浆HBP与其他新型AKI生物标记物的预测性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号